JAMA sub-journal: Does high antibody concentration equal to high protection?

The !-- has more than 22.7 million new crowns diagnosed worldwide.
are looking forward to the approval and use of more than 200 of the best in the new crown vaccine as soon as possible.
these vaccines do show good safety and immunogenicity in animal and clinical trials, but we still need to wait for strong clinical evidence to further demonstrate their effectiveness.
, there is no data to answer how long the immunity generated by these vaccines lasts, and we don't know whether the soliotic and cellular immunity induced by these vaccines can effectively fight the new coronavirus in the human body.
, Professors Wu Fan and Huang Jingho of Fudan University led a team that published an article in jamA Internal Medicine, an American Medical Association journal, exploring the relationship between the nemesis antibodies in 175 patients with neo-coronary mild disease in Shanghai and their clinical characteristics. the
study found that antibody concentrations in older and male patients were significantly higher than in younger and female patients, while symptoms in older and male patients tended to be more severe, meaning that high concentrations of meso-antibodies were not necessarily effective against the new coronavirus and provided new insights into the sources of protection against the new coronary vaccine.
study observed differences in antibody concentrations, and in this study, researchers from Fudan University studied 175 patients with mild illness who were hospitalized for infection between January 24 and February 26 in The Shanghai area.
93 (53 per cent) were women and 82 were men, with a median age of 50.
team detected highly differentiated meso-antibodies in the plasma of these new coronary patients.
during treatment and recovery, no new coronary and antibodies were detected in the plasma of 10 patients, and different concentrations of mesothetic antibodies were detected in the plasma of 165 patients.
including 10 antibody-free patients, the median concentration of new coronary antibodies in all patients was 1076 (IQR, 448-2048), significantly higher than that of the healthy control group.
in 11 patients where antibody concentrations were continuously monitored, the team found that new coronary and antibody levels began to rise 4-6 days after the onset of the disease and peaked at 10-15 days.
After further testing of the antibody concentration after the patient's recovery, the authors found that, consistent with previous reports in the Journal of Nature-Medicine of Chongqing Medical University, the antibody concentration in the patient's body showed a significant decrease after discharge from the hospital, and there was a significant difference in the antibody concentration of 175 patients after rehabilitation.
the antibody concentration of the previous 10 patients without antibodies during the period of illness was still below the detection limit after rehabilitation, with a total of 52 (30%) patients with plasma antibody concentration (ID50) in the low range (median: 327) and 29 (17%). The plasma antibody concentration is in the medium-low range (median: 881), 69 (39%) is in the medium-high range (median: 1642), and the remaining 25 (14%) antibody concentration is in the high range (median: 3800).
in a subsequent analysis, the authors found a more noteworthy phenomenon: 10 patients with antibody concentrations below the detection limit were relatively young, with a median age of 34, while patients with high antibody concentrations had a median age of 63.
, eight of the 10 patients who did not detect antibodies were women.
suggests that the concentration of antibodies after recovery may be related to sex and age.
the authors also compared the sex and age differences in antibody concentrations after recovery.
results showed that 82 men had significantly higher antibody concentrations than 93 women, with a median difference of more than 50 percent (1417 vs. 905).
At the same time, the median antibody concentrations in the elderly group (60-85 years), the middle-aged group (40-59 years old), and the youth group (15-39 years old) were 1537,1291 and 459 years, respectively, and the antibody concentrations of young people were several times lower than those of the middle-aged and elderly.
and numerous previous studies have long shown that men and the elderly have more severe symptoms after contracting the new crown than women and young adults, suggesting that antibody concentrations may be associated with the severity of the symptoms.
high concentration - high protection? The results of this study once again support the significant decline in antibody concentration in patients with new crowns after rehabilitation.
the answer remains to be seen whether the disease will continue to provide patients with adequate immunity after the antibody concentration drops.
review, written by Jama Internal Medicine, points out that, more importantly, the study raises two more serious questions that need to be considered.
first, can the high concentration of antibodies from the vaccine really resist new coronavirus infections? To be sure, a large number of animal and clinical trials of vaccines have demonstrated that they can induce high concentrations of new crowns and the production of antibodies.
in this study, there did not appear to be a direct link between higher concentrations of antibodies and stronger protective effects.
second, do different groups of people need different concentrations of new coronary antibodies? In this study, there were significant differences in antibody concentrations between different people, genders, and ages.
does this mean that different individuals need significantly different amounts of antibodies to fight the new coronavirus.
, for example, if two patients in the study had antibody concentrations above ID50 above 15,000 during their illness, is it only a stronger vaccine that provides protection for such people? The revelations about the development of the new crown vaccine Although vaccine research and development has been reported frequently recently, there are still many people in the academic community who are cautious about the effectiveness of the vaccine.
August 17, the authoritative journal Nature published a news commentary on vaccine research and development.
the authors of the review were optimistic, he did not shy away from addressing two important unresolved questions: 1) How long is the vaccine protected? 2) How many antibodies are needed to protect the inoculator? This study seems to bring some negative news to the second problem, but it also points in some way to a new direction for future vaccine research.
at the end of the study, the authors found that patients with high antibody concentrations also had lower numbers of lymphocytes in their bodies, suggesting that their lymphocytes functioned more weakly while they developed stronger nonse specific immunity in their bodies.
means that perhaps lymphocytes are the key to the immunity provided by the vaccine, and the concentration of antibodies highlighted at this stage may not be as important as we thought.
!--/ewebeditor:page--!--ewebeditor:page-title" -- but the truth is that it will not be known until more vaccine clinical trial data are released.
() !--/ ewebeditor: page--